SEP 8, 2026 · PHASE 3 TRIAL
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
ClinicalTrials.gov
This is a Phase 3 clinical trial registry record with no reported results; the study is active but not recruiting, and efficacy outcomes have not yet been posted.
Reported
Planned enrollment350
PhasePhase 3
Primary endpoint 1Overall Survival (OS), up to approximately…